The Biomedical Advanced Research and Development Authority (BARDA) is doing its part to combat the global problem of antimicrobial resistance (AMR) by incentivizing investments in new antibiotics, including funding through the drug development accelerator CARB-X.
The Pink Sheet spoke with BARDA's Acting Deputy Director Joe Larsen about CARB-X and other ways of providing incentives and increasing investment in antibiotics and antifungals as part of a roundtable discussion conducted during the BIO International Convention last month in San Diego